BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Ann Lab Med 2021;41:16-24. [PMID: 32829576 DOI: 10.3343/alm.2021.41.1.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu PS, Hsieh YC, Lee KC, Huang YH, Hou MC, Lin HC. Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients. PLoS One 2021;16:e0258589. [PMID: 34648567 DOI: 10.1371/journal.pone.0258589] [Reference Citation Analysis]
2 Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Kirino S, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. Int J Mol Sci 2020;22:E40. [PMID: 33375190 DOI: 10.3390/ijms22010040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cheng Y, Wang C. Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Can Predict Mild or Significant Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.115400] [Reference Citation Analysis]
4 Tamaki N, Kurosaki M, Kirino S, Izumi N. Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients. Hepatol Res 2021;51:1170-1. [PMID: 34724296 DOI: 10.1111/hepr.13684] [Reference Citation Analysis]
5 Nam M, Hur M, Park M, Kim H. Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis. Diagnostics 2022;12:628. [DOI: 10.3390/diagnostics12030628] [Reference Citation Analysis]
6 Hur M, Park M, Moon HW, Choe WH, Lee CH. Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer. Ann Lab Med 2022;42:249-57. [PMID: 34635616 DOI: 10.3343/alm.2022.42.2.249] [Reference Citation Analysis]
7 Tamai H, Okamura J, Ohoshi T, Wakasaki H. Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis. Healthcare (Basel) 2021;9:523. [PMID: 33946842 DOI: 10.3390/healthcare9050523] [Reference Citation Analysis]
8 Jang SY, Tak WY, Park SY, Kweon YO, Lee YR, Kim G, Hur K, Han MH, Lee WK. Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases. Ann Lab Med 2021;41:302-9. [PMID: 33303715 DOI: 10.3343/alm.2021.41.3.302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Francque SM. Biomarkers for Liver Fibrosis Post-Liver Transplantation: Not As Easy As It Looks. Liver Transpl 2021;27:327-8. [PMID: 33111474 DOI: 10.1002/lt.25927] [Reference Citation Analysis]
10 Jang TY, Huang CF, Yeh ML, Huang CI, Dai CY, Tsai PC, Hsu PY, Wei YJ, Hou NJ, Liang PC, Lin YH, Wang CW, Hsieh MY, Lin ZY, Huang JF, Yu ML, Chuang WL. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. Kaohsiung J Med Sci 2021. [PMID: 34786828 DOI: 10.1002/kjm2.12474] [Reference Citation Analysis]
11 Nababan SHH, Kalista KF, Jasirwan CO, Kurniawan J, Lesmana CRA, Sulaiman AS, Hasan I, Gani RA. Mac-2 Binding Protein Glycosylation Isomer for Screening High-Risk Esophageal Varices in Liver Cirrhotic Patient. Livers 2021;1:60-7. [DOI: 10.3390/livers1020006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Enomoto N, Izumi N. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther 2021. [PMID: 34927277 DOI: 10.1111/apt.16745] [Reference Citation Analysis]
13 Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. J Viral Hepat 2021;28:787-94. [PMID: 33484033 DOI: 10.1111/jvh.13473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Izumi N. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol 2021. [PMID: 34154037 DOI: 10.1111/jgh.15589] [Reference Citation Analysis]
15 Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatol Commun 2021. [PMID: 34676692 DOI: 10.1002/hep4.1833] [Reference Citation Analysis]